Although an ELK-1(K35N) mutation has been observed in an ovarian carcinoma (60), this is the first report to identify mono-ubiquitination of K35 as a modulator of ELK-1 activity and USP17 as the enzyme responsible for its removal. Here, USP17L9P is linked to ovarian carcinoma.